Moderna, Pfizer move to include HIV-positive volunteers in Phase 3 trials of COVID-19 vaccines

Health organizations including the CDC recommend routine immunization for HIV-positive people, who have been unilaterally left out of vaccine trials so far.

tech2 News Staff August 10, 2020 15:32:12 IST
Moderna, Pfizer move to include HIV-positive volunteers in Phase 3 trials of COVID-19 vaccines

After promising results from early-stage trials of two key vaccine candidates against the coronavirus, vaccine candidates from Moderna-NIAID and Oxford-AstraZeneca entered final stage of human trials in August. Now, Moderna and Pfizer (which has partnered with German biotech firm BioNTech to develop a COVID-19 vaccine) have announced that they will be including a limited number of HIV-positive volunteers in the final stage of trials, after initially having excluded them.

So far, all human trials for a COVID-19 vaccine have excluded participants with pre-existing conditions and co-morbidities. The protocol for the NIAID-Moderna vaccine, for instance, excludes those with an "immunosuppressive or immunodeficient state, including human immunodeficiency virus (HIV) infection." The protocol for the Oxford-AstraZeneca trial excludes people with "any confirmed or suspected immunosuppressive or immunodeficient state" without specifying HIV.

However, advocates have argued that with modern antiretroviral therapy, most HIV-positive people on treatment do not experience any immune suppression. Instead, the human immunodeficiency virus (HIV) is prevented from replicating and affecting immune cells, which are often at near-normal levels. There are studies showing that people living with HIV are not at any greater a risk for SARS-CoV-2 infection, and neither are they more likely to develop severe COVID-19 or to die from it.

"Decades of research have proven that HIV-positive people with undetectable viral loads and a safe CD4 count respond to vaccines, and are encouraged to receive all recommended vaccinations," Jeff Taylor of the HIV+Aging Research Project told POZ. "It should give us pause to see an inexperienced company with a lack of basic scientific knowledge is in charge of a hugely important vaccine trial — at a huge cost to taxpayers," he added.

Moderna Pfizer move to include HIVpositive volunteers in Phase 3 trials of COVID19 vaccines

Decades of research have proven that HIV-positive people with undetectable viral loads and a safe CD4 count respond to vaccines. AFP

The exclusion was overturned – first in the Moderna vaccine trial and later, in the Pfizer vaccine trials – after advocates submitted a Change.org petition to the US National Institute of Health AIDS Director Francis Collins, citing that Moderna's trial "excludes people with HIV with no scientific basis."

Moreover, many health organizations including the US Centre for Disease Prevention and Control recommend routine immunizations for HIV-positive people. The only caveat, as per the CDC website, is for "live vaccines, if the CD4 T cell count is below 200", the petition pointed out.

On 5 August, Moderna tweeted that its Phase 3 COVID-19 vaccine trials would adapt to "include people living with controlled HIV who are not otherwise immunosuppressed." The company had planned to test the vaccine in HIV patients in a separate study, but “heard the preference of the community,” it said, to be part of the ongoing trial.

Pfizer, too, in a 7 August letter to the petition signatories, said that is has amended its protocol to open up the trial to HIV patients in phase II/III of its vaccine study, as well as people who have been treated for hepatitis B and hepatitis C in the past.

In the same vein, debate has emerged around pregnancy. While the pregnant women group is far less activist-driven than the HIV community, they too have been left out of safety and efficacy trials throughout, something scientists and ethicists have acknowledged.

Updated Date:

also read

DCGI shares draft guidelines for pharma giants manufacturing, distributing COVID-19 vaccines
India

DCGI shares draft guidelines for pharma giants manufacturing, distributing COVID-19 vaccines

Dr Balram Bhargava, Director-General of ICMR said, "There are three things for a vaccine--(i) the safety, (ii) immunogenicity, and (iii) the efficacy."

Rich nations with 13% of world's population secure over half COVID-19 vaccine in late-stage trials, says Oxfam report
World

Rich nations with 13% of world's population secure over half COVID-19 vaccine in late-stage trials, says Oxfam report

At least, 51% of 5.9 billion doses expected to be available for supply post successful trials have been snapped up by the US, Britian, Australia, Japan, Switzerland, Israel, the EU and Hong Kong and Macau, the report claimed

SinoVac announces Coronavirus vaccine to be ready for distribution by 2021
science

SinoVac announces Coronavirus vaccine to be ready for distribution by 2021

While the vaccine has not yet passed the phase 3 clinical trials, SinoVac has already injected thousands of people in China under an emergency use provision.